Drug intelligence / Profile preview

Angiotensin Therapeutic Vaccine + CoVaccine HT

Development stage: Discontinued
Lead developer: Bio-Technology General
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

A therapeutic vaccine for hypertension that combines an angiotensin component with CoVaccine HT, a novel adjuvant. The vaccine targets the renin-angiotensin system to generate antibodies against angiotensin, aiming to reduce blood pressure in hypertensive patients. This approach was designed to address poor patient compliance with daily medication by requiring only a few injections over time rather than daily pills.

Beyond the preview

Go deeper on Angiotensin Therapeutic Vaccine + CoVaccine HT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiotensin Therapeutic Vaccine + CoVaccine HT.

Explore the full profile